Your browser doesn't support javascript.
loading
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer, C E; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; Cui, K; Arahmani, A; Aktan, G; Armstrong, A C; Arnedos, M; Balmaña, J; Bergh, J; Bliss, J; Delaloge, S; Domchek, S M; Eisen, A; Elsafy, F; Fein, L E; Fielding, A; Ford, J M; Friedman, S; Gelmon, K A; Gianni, L; Gnant, M; Hollingsworth, S J; Im, S-A; Jager, A; Jóhannsson, Ó Þ; Lakhani, S R; Janni, W; Linderholm, B; Liu, T-W; Loman, N; Korde, L; Loibl, S; Lucas, P C; Marmé, F; Martinez de Dueñas, E; McConnell, R; Phillips, K-A; Piccart, M; Rossi, G; Schmutzler, R; Senkus, E; Shao, Z; Sharma, P; Singer, C F; Spanic, T.
Afiliación
  • Geyer CE; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh.
  • Garber JE; Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Gelber RD; Dana-Farber Cancer Institute, Harvard Medical School, Boston; Harvard T.H. Chan School of Public Health, Boston; Frontier Science Foundation, Boston.
  • Yothers G; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA.
  • Taboada M; Oncology Biometrics Department, AstraZeneca, Macclesfield.
  • Ross L; Department of Data Management, Frontier Science (Scotland), Kincraig, Scotland, UK.
  • Rastogi P; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh.
  • Cui K; Department of Oncology R&D, AstraZeneca, Gaithersburg, USA.
  • Arahmani A; Research Operations Department, Breast International Group, Brussels, Belgium.
  • Aktan G; Global Oncology Clinical Development, Merck and Co. Inc., Rahway, USA.
  • Armstrong AC; Department of Medical Oncology, The Christie Hospital NHS Foundation Trust Manchester, UK.
  • Arnedos M; European Organisation for Research and Treatment (EORTC), Brussels, Belgium; The Department of Medical Oncology, Institut Bergonie, Bordeaux, France.
  • Balmaña J; Medical Oncology Department, Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona, Spain.
  • Bergh J; Department of Oncology-Pathology, Swedish Breast Cancer Group, Karolinska Institute and Breast Cancer Center, Karolinska University Hospital and Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
  • Bliss J; Department of Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK.
  • Delaloge S; Department of Cancer Medicine, Institute Gustave Roussy and Unicancer Breast Group, Paris, France.
  • Domchek SM; Department of Medicine, Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
  • Eisen A; Odette Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada.
  • Elsafy F; Oncology Biometrics Department, AstraZeneca, Macclesfield.
  • Fein LE; Department of Clinical Research, Instituto de Oncologia De Rosario, Santa Fe, Argentina.
  • Fielding A; Department of Oncology R&D, AstraZeneca, Gaithersburg, USA.
  • Ford JM; Department of Medicine/Oncology, Stanford University School of Medicine, Stanford.
  • Friedman S; Facing Our Risk of Cancer Empowered, Tampa, USA.
  • Gelmon KA; Department of Medical Oncology, BC Cancer, Vancouver, Canada.
  • Gianni L; Department of Oncology, International Breast Cancer Study Group, Bern, Switzerland; Department of Medical Oncology, Ospedale Infermi AUSL della Romagna, Rimini, Italy.
  • Gnant M; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Hollingsworth SJ; Department of Late Development Oncology, AstraZeneca, Cambridge, UK.
  • Im SA; Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Jager A; Department of Medical Oncology, Dutch Breast Cancer Research Group, Utrecht, the Netherlands.
  • Jóhannsson ÓÞ; Department of Medical Oncology, Landspítali University Hospital of Iceland, Icelandic Breast Cancer Group, Reykjavik, Iceland.
  • Lakhani SR; Department of Anatomical Pathology, The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia.
  • Janni W; Department for Obstetrics and Gynecology, Universitaetsklinikum, University of Ulm, Ulm, Germany.
  • Linderholm B; Department of Oncology, Sahlgrenska University Hospital, Gothenburg; Department of Oncology, The Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
  • Liu TW; Division of Cancer Research, National Health Research Institutes, Taiwan Cooperative Oncology Group, Taipei City, Taiwan.
  • Loman N; Department of Hematology, Oncology, and Radiation Physics, Swedish Association of Breast Oncologists, Skåne University Hospital, Lund, Sweden.
  • Korde L; Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, The National Cancer Institute, Rockville, USA.
  • Loibl S; Medicine and Research, German Breast Group, Neu-Isenburg; Medicine and Research, The Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt, Germany.
  • Lucas PC; NRG Oncology/NSABP Foundation, Pittsburgh; Department of Pathology, UPMC Hillman Cancer Center, Pittsburgh, USA.
  • Marmé F; Medical Faculty Mannheim, Heidelberg University, Mannheim Germany and the German Breast Group, Neu-Isenburg, Germany.
  • Martinez de Dueñas E; Médica Consorcio Hospitalario Provincial de Castellón, Servicio de Oncología, Castellón, Spain.
  • McConnell R; Department of Data Management, Frontier Science (Scotland), Kincraig, Scotland, UK.
  • Phillips KA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Breast Cancer Trials, Australia and New Zealand, Newcastle, Australia.
  • Piccart M; Department of Scientific Direction, Institut Jules Bordet, l'Université Libre de Bruxelles, Brussels.
  • Rossi G; Department of Research and Development, Breast International Group, Brussels, Belgium.
  • Schmutzler R; The Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
  • Senkus E; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
  • Shao Z; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Sharma P; Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, USA.
  • Singer CF; Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Spanic T; Department of Patient Advocacy, Europa Donna-The European Breast Cancer Coalition, Milan, Italy; Europa Donna Slovenia, Ljubljana, Slovenia.
Ann Oncol ; 33(12): 1250-1268, 2022 12.
Article en En | MEDLINE | ID: mdl-36228963
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article